Please assess the completion status of the following clinical trial:

Trial Title: Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Meets DSM-IV criteria for both alcohol and cocaine dependence, as determined by the Structured Clinical Interview(SCID-IV)~* Successful completion of alcohol detoxification (i.e., 3 consecutive days of abstinence from alcohol)~* Use of at least $100 worth of cocaine in the 30 days prior to enrollment~* In the past 30 days, Subject used no less than $100 worth of cocaine and drank a minimum of 12 standard alcohol drinks/week (on average), having at least four days in 30 where at least four or more drinks were ingested, as determined by the Timeline Followback (TLFB) - adapted to collect daily cocaine use;~* Able to commute to the treatment research center~* Speaks, understands, and writes English~* Understands and signs the informed consent.~Exclusion Criteria:~* Abstinence from alcohol or cocaine for more than 30 days before signing consent form~* Current DSM-IV diagnosis of any psychoactive substance dependence other than Alcohol, Cocaine or Nicotine dependence, as determined by the SCID;~* Evidence of opiate use in the past 30 days as assessed by self-report and intake urine drug screen;~* History of unstable or serious medical illness, including need for opioid analgesics;~* Concomitant treatment with phenytoin or from same drug class, lithium, serotonin selective reuptake inhibitors, tricyclic antidepressants, MAOI's or narcotics; 6) Use of any investigational medication within the past 30 days;~* Severe physical or medical illness such as AIDS, active hepatitis or significant hepatocellular injury as evidenced by elevated bilirubin levels;~* Severe psychiatric symptoms, e.g., psychosis, suicidal or homicidal ideation or mania;~* Female patients who are pregnant, nursing, or not using a reliable method of contraception. Acceptable methods of birth control include: barrier (diaphragm or condom) with spermicide, intrauterine progesterone contraceptive system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection, oral contraceptives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Naltrexone (Type: EXPERIMENTAL): Naltrexone
- Disulfiram (Type: EXPERIMENTAL): Disulfiram
- Naltrexone and Disulfiram (Type: EXPERIMENTAL): Naltrexone and Disulfiram
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).